A panoply of errors: polymerase proofreading domain m

Nature Reviews Cancer

16, 71-81

DOI: 10.1038/nrc.2015.12

Citation Report

#	Article	IF	Citations
1	Roles of human POLD1 and POLD3 in genome stability. Scientific Reports, 2016, 6, 38873.	1.6	46
2	Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4723-4728.	3.3	100
3	Human Cancers Express a Mutator Phenotype: Hypothesis, Origin, and Consequences. Cancer Research, 2016, 76, 2057-2059.	0.4	84
4	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	3.7	227
5	Redox Signaling through DNA. Israel Journal of Chemistry, 2016, 56, 705-723.	1.0	15
6	Regression of Chemotherapy-Resistant Polymerase Ïµ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clinical Cancer Research, 2016, 22, 5682-5687.	3.2	145
7	Molecular Pathology. Surgical Pathology Clinics, 2016, 9, 405-426.	0.7	17
8	POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies. Gene, 2016, 590, 128-141.	1.0	98
9	DNA Replicationâ€"A Matter of Fidelity. Molecular Cell, 2016, 62, 745-755.	4.5	115
10	Helicobacter pylori-Mediated Genetic Instability and Gastric Carcinogenesis. Current Topics in Microbiology and Immunology, 2017, 400, 305-323.	0.7	25
11	Eukaryotic DNA Replication Fork. Annual Review of Biochemistry, 2017, 86, 417-438.	5.0	365
12	Function of the Plant DNA Polymerase Epsilon in Replicative Stress Sensing, a Genetic Analysis. Plant Physiology, 2017, 173, 1735-1749.	2.3	26
13	Hypermutated Colorectal Cancer and Neoantigen Load. , 2017, , 187-215.		3
14	Alterations in cellular metabolism triggered by URA7 or GLN3 inactivation cause imbalanced dNTP pools and increased mutagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4442-E4451.	3.3	30
15	Mutational signatures and mutable motifs in cancer genomes. Briefings in Bioinformatics, 2017, 19, 1085-1101.	3.2	32
16	Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy. DNA Repair, 2017, 56, 16-25.	1.3	84
17	DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discovery, 2017, 7, 675-693.	7.7	519
18	The interaction between cytosine methylation and processes of DNA replication and repair shape the mutational landscape of cancer genomes. Nucleic Acids Research, 2017, 45, 7786-7795.	6.5	78

#	Article	IF	Citations
19	Evolutionary dynamics and significance of multiple subclonal mutations in cancer. DNA Repair, 2017, 56, 7-15.	1.3	16
20	Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. Critical Reviews in Oncology/Hematology, 2017, 113, 242-248.	2.0	68
21	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	1.4	85
22	Characterization of a novel POLD1 missense founder mutation in a Spanish population. Journal of Gene Medicine, 2017, 19, e2951.	1.4	4
23	Polymerase Îµ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecologic Oncology, 2017, 144, 146-152.	0.6	55
24	Molecular approaches for classifying endometrial carcinoma. Gynecologic Oncology, 2017, 145, 200-207.	0.6	137
25	Mutational analysis of hypermutation-related POLE gene in acute leukemias and lymphomas. Experimental Hematology, 2017, 48, 39-40.	0.2	0
27	Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565.	2.1	102
28	Universal Patterns of Selection in Cancer and Somatic Tissues. Cell, 2017, 171, 1029-1041.e21.	13.5	1,085
29	Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. European Journal of Cancer, 2017, 84, 290-303.	1.3	112
30	Tumor Evolution as a Therapeutic Target. Cancer Discovery, 2017, 7, 805-817.	7.7	158
31	Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours. Journal of Pathology, 2017, 243, 331-341.	2.1	12
32	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552, 116-120.	13.7	480
33	Multilevel genomics of colorectal cancers with microsatellite instabilityâ€"clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine, 2017, 9, 46.	3.6	71
34	Cancer predisposition syndromes: lessons for truly precision medicine. Journal of Pathology, 2017, 241, 226-235.	2.1	13
35	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatinâ€remodelling genes as major players and a prognostic role for <scp>TERT</scp>, <scp>RB1</scp>, <scp>MEN1</scp> and <scp>KMT2D</scp>. Journal of Pathology, 2017, 241, 488-500.	2.1	179
36	The pathological consequences of impaired genome integrity in humans; disorders of the DNA replication machinery. Journal of Pathology, 2017, 241, 192-207.	2.1	11
37	Abrupt transitions to tumor extinction: a phenotypic quasispecies model. Journal of Mathematical Biology, 2017, 74, 1589-1609.	0.8	13

#	Article	IF	Citations
38	Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis. Journal of Gastroenterology, 2017, 52, 26-38.	2.3	63
39	Recent Discoveries in the Genetics of Familial Colorectal CancerÂand Polyposis. Clinical Gastroenterology and Hepatology, 2017, 15, 809-819.	2.4	66
40	10 Iron-sulfur proteins and human diseases. , 2017, , 227-306.		0
41	Genomic Destabilization Triggered by Replication Stress during Senescence. Cancers, 2017, 9, 159.	1.7	4
42	Risks at the DNA Replication Fork: Effects upon Carcinogenesis and Tumor Heterogeneity. Genes, 2017, 8, 46.	1.0	27
43	Human DNA polymerase delta double-mutant D316A;E318A interferes with DNA mismatch repair in vitro. Nucleic Acids Research, 2017, 45, 9427-9440.	6.5	4
44	POLEandPOLD1screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget, 2017, 8, 26732-26743.	0.8	40
45	Comprehensive Molecular Characterization of Urachal Adenocarcinoma Reveals Commonalities With Colorectal Cancer, Including a Hypermutable Phenotype. JCO Precision Oncology, 2017, 1, 1-12.	1.5	17
46	Fidelity of DNA replicationâ€”a matter of proofreading. Current Genetics, 2018, 64, 985-996.	0.8	109
47	Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Journal of Pathology, 2018, 245, 283-296.	2.1	71
48	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	13.5	2,111
49	The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. Journal of Pathology, 2018, 244, 538-549.	2.1	172
50	Noise-induced bistability in the fate of cancer phenotypic quasispecies: a bit-strings approach. Scientific Reports, 2018, 8, 1027.	1.6	14
51	Functional Analysis of Cancer-Associated DNA Polymerase Îµ Variants inSaccharomyces cerevisiae. G3: Genes, Genomes, Genetics, 2018, 8, 1019-1029.	0.8	49
52	Microarray analysis of obese women with polycystic ovary syndrome for key gene screening, key pathway identification and drug prediction. Gene, 2018, 661, 85-94.	1.0	8
53	Adjuvant Treatment for POLE Proofreading Domainâ€“Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. Clinical Cancer Research, 2018, 24, 3197-3203.	3.2	50
54	DNA Replication and associated repair pathways are involved in the mutagenesis of methylated cytosine. DNA Repair, 2018, 62, 1-7.	1.3	25
55	NTHL1 and MUTYH polyposis syndromes: two sides of the same coin?. Journal of Pathology, 2018, 244, 135-142.	2.1	63

#	Article	IF	Citations
56	Blinded histopathological characterisation of <scp>POLE</scp> exonuclease domainâ€mutant endometrial cancers: sheep in wolf's clothing. Histopathology, 2018, 72, 248-258.	1.6	34
57	DNA Repair Deficiency and Immunotherapy Response. Journal of Clinical Oncology, 2018, 36, 1710-1713.	0.8	31
58	Reduced structural flexibility for an exonuclease deficient DNA polymerase III mutant. Physical Chemistry Chemical Physics, 2018, 20, 26892-26902.	1.3	11
59	Therapy Implications of DNA Mismatch Repair Deficiency, Microsatellite Instability, and Tumor Mutation Burden. Advances in Molecular Pathology, 2018, 1, 193-208.	0.2	5
60	The DNA damage response in immunotherapy and radiation. Advances in Radiation Oncology, 2018, 3, 527-533.	0.6	24
61	Translational geroscience: From invertebrate models to companion animal and human interventions. Translational Medicine of Aging, 2018, 2, 15-29.	0.6	20
62	POLE gene hotspot mutations in advanced pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2161-2166.	1.2	15
63	Adenocarcinoma, Carcinosarcoma, and Other Epithelial Tumors of the Endometrium. , 2018, , 582-651.		0
64	Gynecologic Cancers. Clinics in Laboratory Medicine, 2018, 38, 421-438.	0.7	9
65	Diseases Associated with Mutation of Replication and Repair Proteins. Advances in Experimental Medicine and Biology, 2018, 1076, 215-234.	0.8	5
66	Drosophila Models for Human Diseases. Advances in Experimental Medicine and Biology, 2018, , .	0.8	13
67	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers, 2018, 10, 39.	1.7	44
68	Eukaryotic DNA polymerases. Current Opinion in Structural Biology, 2018, 53, 77-87.	2.6	84
69	Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. Biology, 2018, 7, 5.	1.3	3
70	Probing DNA Base-Dependent Leaving Group Kinetic Effects on the DNA Polymerase Transition State. Biochemistry, 2018, 57, 3925-3933.	1.2	18
71	Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases. Gastric Cancer, 2019, 22, 323-334.	2.7	17
72	Essential Saccharomyces cerevisiae genome instability suppressing genes identify potential human tumor suppressors. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17377-17382.	3.3	8
73	Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncology, 2019, 5, 1504.	3.4	287

#	Article	IF	Citations
74	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget, 2019, 10, 4018-4025.	0.8	118
75	DNA polymerases in the risk and prognosis of colorectal and pancreatic cancers. Mutagenesis, 2019, 34, 363-374.	1.0	3
76	Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. Scientific Reports, 2019, 9, 15767.	1.6	34
77	C. Riley Snorton. Black on Both Sides: A Racial History of Trans Identity.. American Historical Review, 2019, 124, 1464-1465.	0.0	0
78	Plant DNA Polymerases. International Journal of Molecular Sciences, 2019, 20, 4814.	1.8	16
79	Cryo-EM structure and dynamics of eukaryotic DNA polymerase Î´ holoenzyme. Nature Structural and Molecular Biology, 2019, 26, 955-962.	3.6	40
80	Detection of POLE Subtypes in High-Grade Endometrioid Carcinoma by BaseScope-ISH Assay. Frontiers in Oncology, 2019, 9, 831.	1.3	18
81	Hereditary Colorectal Cancer Syndromes. Seminars in Oncology Nursing, 2019, 35, 58-78.	0.7	15
82	A recurrent cancer-associated substitution in DNA polymerase Îµ produces a hyperactive enzyme. Nature Communications, 2019, 10, 374.	5.8	59
83	Structural consequence of the most frequently recurring cancer-associated substitution in DNA polymerase Îµ. Nature Communications, 2019, 10, 373.	5.8	40
84	Defining the impact of mutation accumulation on replicative lifespan in yeast using cancer-associated mutator phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3062-3071.	3.3	17
85	Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene. Cancer Medicine, 2019, 8, 4587-4597.	1.3	23
86	Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. Molecular Aspects of Medicine, 2019, 69, 123-129.	2.7	30
87	Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient. Journal of Human Genetics, 2019, 64, 729-740.	1.1	7
88	Defective DNA Polymerase Î±-Primase Leads to X-Linked Intellectual Disability Associated with Severe Growth Retardation, Microcephaly, and Hypogonadism. American Journal of Human Genetics, 2019, 104, 957-967.	2.6	32
89	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treatment Reviews, 2019, 76, 22-32.	3.4	224
90	Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing. Clinical and Experimental Medicine, 2019, 19, 393-400.	1.9	9
91	Molecular Diagnostics in Colorectal Cancer. , 2019, , 143-155.		2

#	Article	IF	Citations
92	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. Cancer Immunology Research, 2019, 7, 784-796.	1.6	141
93	PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma. Molecular Medicine, 2019, 25, 11.	1.9	28
94	Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecologic Oncology, 2019, 153, 471-478.	0.6	18
95	Phenotype of POLE-mutated endometrial cancer. PLoS ONE, 2019, 14, e0214318.	1.1	53
96	POLE proofreading defects: Contributions to mutagenesis and cancer. DNA Repair, 2019, 76, 50-59.	1.3	44
98	Germline POLE mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. Journal of Physical Education and Sports Management, 2019, 5, a004499.	0.5	19
99	Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. JCO Precision Oncology, 2019, 3, 1-9.	1.5	47
100	Incorporating Colorectal Cancer Genetic Risk Assessment into Gastroenterology Practice. Current Treatment Options in Gastroenterology, 2019, 17, 702-715.	0.3	5
101	POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF/AMFR signal transduction. BMC Medical Genetics, 2019, 20, 202.	2.1	21
102	Human papillomavirus and the landscape of secondary genetic alterations in oral cancers. Genome Research, 2019, 29, 1-17.	2.4	166
103	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clinical Cancer Research, 2019, 25, 1087-1097.	3.2	113
104	NovelPOLEpathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures. Human Mutation, 2019, 40, 36-41.	1.1	21
105	Germline mutation p.N363K in POLE is associated with an increased risk of colorectal cancer and giant cell glioblastoma. Familial Cancer, 2019, 18, 173-178.	0.9	27
106	Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase Îµ (<scp>POLE</scp>). Histopathology, 2020, 76, 366-374.	1.6	15
107	Interpretation of somatic POLE mutations in endometrial carcinoma. Journal of Pathology, 2020, 250, 323-335.	2.1	203
108	Biomarkers for Response to Immune Checkpoint Blockade. Annual Review of Cancer Biology, 2020, 4, 331-351.	2.3	29
109	Inactivating Mutations in Exonuclease and Polymerase Domains in DNA Polymerase Delta Alter Sensitivities to Inhibitors of dNTP Synthesis. DNA and Cell Biology, 2020, 39, 50-56.	0.9	6
110	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. Targeted Oncology, 2020, 15, 11-24.	1.7	65

#	Article	IF	Citations
111	Adenomatous and serrated polyposis syndromes. Diagnostic Histopathology, 2020, 26, 1-7.	0.2	0
112	National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract. European Journal of Medical Genetics, 2020, 63, 104080.	0.7	11
113	Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. Journal of Clinical Oncology, 2020, 38, 3388-3397.	0.8	398
114	Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain. BMC Medical Genetics, 2020, 21, 167.	2.1	2
115	Mismatch repair and DNA polymeraseÂÎ´Âproofreading prevent catastrophic accumulation of leading strand errors in cells expressing a cancer-associated DNA polymeraseÂÏµÂvariant. Nucleic Acids Research, 2020, 48, 9124-9134.	6.5	11
116	Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer. , 2020, 8, e000881.		22
117	Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. Cancer Research, 2020, 80, 5606-5618.	0.4	14
118	POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women. Gynecologic Oncology, 2020, 159, 36-42.	0.6	24
119	Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.1	12
120	POLE Mutation Characteristics in a Chinese Cohort with Endometrial Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 7305-7316.	1.0	5
121	Structure of eukaryotic DNA polymerase Î´ bound to the PCNA clamp while encircling DNA. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30344-30353.	3.3	41
122	DNA Polymerases at the Eukaryotic Replication Fork Thirty Years after: Connection to Cancer. Cancers, 2020, 12, 3489.	1.7	15
123	Impact of Helicobacter pylori Infection and Its Major Virulence Factor CagA on DNA Damage Repair. Microorganisms, 2020, 8, 2007.	1.6	9
124	New Mechanism of Gemcitabine and Its Phosphates: DNA Polymerization Disruption via 3â€²â€“5â€² Exonuclease Inhibition. Biochemistry, 2020, 59, 4344-4352.	1.2	8
125	PrÃzisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. Karger Kompass Pneumologie, 2020, 8, 300-317.	0.0	1
126	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. BioDrugs, 2020, 34, 749-762.	2.2	5
127	Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction. Genetics in Medicine, 2020, 22, 1533-1541.	1.1	17
128	High polymerase Îµ expression associated with increased CD8+T cells improves survival in patients with non-small cell lung cancer. PLoS ONE, 2020, 15, e0233066.	1.1	4

#	Article	IF	Citations
129	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers, 2020, 12, 1125.	1.7	43
130	Prostate carcinogenesis: inflammatory storms. Nature Reviews Cancer, 2020, 20, 455-469.	12.8	114
131	Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. Gene Expression, 2020, 20, 53-65.	0.5	65
132	The first case report of polymerase proofreading-associated polyposis in POLD1 variant, c.1433G>A p.S478N, in Japan. Japanese Journal of Clinical Oncology, 2020, 50, 1080-1083.	0.6	4
133	Molecular Aspects of Colorectal Adenomas: The Interplay among Microenvironment, Oxidative Stress, and Predisposition. BioMed Research International, 2020, 2020, 1-19.	0.9	34
134	Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes. JAMA Oncology, 2020, 6, 588.	3.4	1
135	Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomesâ€"Reply. JAMA Oncology, 2020, 6, 590.	3.4	3
136	A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo. Nature Genetics, 2020, 52, 146-159.	9.4	110
137	Pembrolizumab for the treatment of colorectal cancer. Expert Opinion on Biological Therapy, 2020, 20, 219-226.	1.4	21
138	Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors. Clinical and Translational Gastroenterology, 2020, 11, e00149.	1.3	8
139	Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability. , 2020, 8, e000128.		11
140	Ultraâ€mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns. Cancer Medicine, 2021, 10, 135-142.	1.3	18
141	The orphan nuclear receptor NR0B2 could be a novel susceptibility locus associated with microsatelliteâ€stable, APC mutationâ€negative earlyâ€onset colorectal carcinomas with metabolic manifestation. Genes Chromosomes and Cancer, 2021, 60, 61-72.	1.5	5
142	Integrated Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes. SSRN Electronic Journal, 0, , .	0.4	0
143	Unraveling the genomic landscape of colorectal cancer through mutational signatures. Advances in Cancer Research, 2021, 151, 385-424.	1.9	14
144	Immunotherapy in colorectal cancer: current achievements and future perspective. International Journal of Biological Sciences, 2021, 17, 3837-3849.	2.6	132
145	Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor. Annals of Translational Medicine, 2021, 9, 129-129.	0.7	24
146	Immunotherapy for the treatment of colorectal cancer. Journal of Surgical Oncology, 2021, 123, 760-774.	0.8	18

#	Article	IF	Citations
147	Identification of a metabolic-related gene signature predicting the overall survival for patients with stomach adenocarcinoma. PeerJ, 2021, 9, e10908.	0.9	9
149	Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. Journal of Pathology, 2021, 253, 355-365.	2.1	62
150	The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions. Cancers, 2021, 13, 1478.	1.7	65
151	The Inherited and Familial Component of Early-Onset Colorectal Cancer. Cells, 2021, 10, 710.	1.8	41
152	Complete Response to Pembrolizumab in Advanced Colon Cancer Harboring Somatic POLE F367S Mutation with Microsatellite Stability Status: A Case Study. OncoTargets and Therapy, 2021, Volume 14, 1791-1796.	1.0	7
153	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. Clinical Cancer Research, 2021, 27, 3234-3242.	3.2	24
155	Compensation for the absence of the catalytically active half of DNA polymerase Îµ in yeast by positively selected mutations in CDC28. Genetics, 2021, 218, .	1.2	7
156	An MHV-68 Mutator Phenotype Mutant Virus, Confirmed by CRISPR/Cas9-Mediated Gene Editing of the Viral DNA Polymerase Gene, Shows Reduced Viral Fitness. Viruses, 2021, 13, 985.	1.5	1
157	Underappreciated Roles of DNA Polymerase Î´ in Replication Stress Survival. Trends in Genetics, 2021, 37, 476-487.	2.9	22
158	MIF is a 3â€™ flap nuclease that facilitates DNA replication and promotes tumor growth. Nature Communications, 2021, 12, 2954.	5.8	20
159	Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications. Frontiers in Oncology, 2021, 11, 648687.	1.3	29
160	Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. Clinical Epigenetics, 2021, 13, 117.	1.8	8
161	FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. Frontiers in Oncology, 2021, 11, 683419.	1.3	84
162	The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy. Current Drug Targets, 2021, 22, 1021-1033.	1.0	6
163	Clinical utility of whole-genome sequencing in precision oncology. Seminars in Cancer Biology, 2022, 84, 32-39.	4.3	35
164	Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer. , 2021, 9, e002356.		35
165	Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomarker Research, 2021, 9, 49.	2.8	53
166	Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. BMC Medical Genomics, 2021, 14, 165.	0.7	10

#	Article	IF	Citations
167	Expression of the cancer-associated DNA polymerase Îµ P286R in fission yeast leads to translesion synthesis polymerase dependent hypermutation and defective DNA replication. PLoS Genetics, 2021, 17, e1009526.	1.5	8
168	The stabilized Pol31â€“Pol3 interface counteracts Pol32 ablation with differential effects on repair. Life Science Alliance, 2021, 4, e202101138.	1.3	1
169	Solving the enigma of POLD1 p.V295M as a potential cause of increased cancer risk. European Journal of Human Genetics, 2022, 30, 485-489.	1.4	2
171	POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. Oncogene, 2021, 40, 5893-5901.	2.6	34
172	Characterization of DNA polymerase Î´ from deep-sea hydrothermal vent shrimp Rimicaris exoculata. Acta Oceanologica Sinica, 2021, 40, 168-175.	0.4	0
173	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Frontiers in Oncology, 2021, 11, 716844.	1.3	12
174	Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients. Frontiers in Genetics, 2021, 12, 608742.	1.1	5
175	Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence. International Journal of Gynecological Pathology, 2022, 41, 207-219.	0.9	5
176	Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors. Immunotherapy, 2021, 13, 1205-1213.	1.0	0
177	Current status and future perspective of immune checkpoint inhibitors in colorectal cancer. Cancer Letters, 2021, 521, 119-129.	3.2	16
178	Colorectal Cancer: A Model for the Study of Cancer Immunology. , 2021, , 15-30.		0
179	POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting. International Journal of Gynecological Pathology, 2021, 40, 5-16.	0.9	37
181	A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight, 2020, 5, .	2.3	25
182	Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load. Journal of Clinical Investigation, 2018, 128, 4179-4191.	3.9	56
183	Polymerase Î´ deficiency causes syndromic immunodeficiency with replicative stress. Journal of Clinical Investigation, 2019, 129, 4194-4206.	3.9	41
184	Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B. PLoS ONE, 2016, 11, e0155391.	1.1	33
185	Yeast-based assays for the functional characterization of cancer-associated variants of human DNA repair genes. Microbial Cell, 2020, 7, 162-174.	1.4	10
186	First description of ultramutated endometrial cancer caused by germline loss-of-function and somatic exonuclease domain mutations in POLE gene. Genetics and Molecular Biology, 2020, 43, e20200100.	0.6	2

#	Article	IF	Citations
188	Whole-exome sequencing identified mutational profiles of high-grade colon adenomas. Oncotarget, 2017, 8, 6579-6588.	0.8	27
189	Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer. Oncotarget, 2017, 8, 25542-25551.	0.8	15
190	Human DNA polymerase delta requires an ironâ€“sulfur cluster for high-fidelity DNA synthesis. Life Science Alliance, 2019, 2, e201900321.	1.3	25
191	Explosive mutation accumulation triggered by heterozygous human Pol Îµ proofreading-deficiency is driven by suppression of mismatch repair. ELife, 2018, 7, .	2.8	33
192	Pembrolizumab in endometrial cancer: Where we stand now (Review). Oncology Letters, 2021, 22, 821.	0.8	10
193	Biomarkers of immunotherapy response in breast cancer beyond PD-L1. Breast Cancer Research and Treatment, 2022, 191, 39-49.	1.1	11
196	Medical Oncology Management of Hereditary Colorectal Cancer. , 2018, , 401-413.		0
198	A simple but profound mutation in mouse DNA polymerase Îµ drives tumorigenesis. Journal of Clinical Investigation, 2018, 128, 3754-3756.	3.9	1
201	More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology. European Medical Journal Oncology, 0, , 43-52.	0.0	1
202	Analysis of Mutations and Dysregulated Pathways Unravels Carcinogenic Effect and Clinical Actionability of Mutational Processes. Frontiers in Cell and Developmental Biology, 2021, 9, 768981.	1.8	1
203	Constitutional POLE variants causing a phenotype reminiscent of constitutional mismatch repair deficiency. Human Mutation, 2022, 43, 85-96.	1.1	8
204	Biomarker-driven immunotherapy for precision medicine in prostate cancer. Personalized Medicine, 2022, 19, 51-66.	0.8	1
205	DNA Repair Genes Are Associated with Subtype Classification, Prognosis, and Immune Infiltration in Uveal Melanoma. Journal of Oncology, 2022, 2022, 1-18.	0.6	4
206	Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology, 2022, 80, 762-778.	1.6	46
207	OUP accepted manuscript. Oncologist, 2022, 27, 245-250.	1.9	1
208	Endoscopic management of non-ampullary duodenal adenomas. Endoscopy International Open, 2022, 10, E96-E108.	0.9	5
210	Nueva clasificaciÃ³n molecular del carcinoma de endometrio: impacto en el diagnÃ³stico histopatolÃ³gico, tratamiento y pronÃ³stico. Medunab, 2022, 24, 365-374.	0.0	0
211	Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World Journal of Gastrointestinal Oncology, 2022, 14, 19-37.	0.8	2

#	Article	IF	Citations
212	OUP accepted manuscript. Oncologist, 2022, 27, 159-162.	1.9	4
213	Probing the mechanisms of two exonuclease domain mutators of DNA polymerase Ïµ. Nucleic Acids Research, 2022, 50, 962-974.	6.5	7
214	PrimPol: A Breakthrough among DNA Replication Enzymes and a Potential New Target for Cancer Therapy. Biomolecules, 2022, 12, 248.	1.8	6
215	Clinical and Molecular Characterization ofPOLEMutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precision Oncology, 2022, 6, e2100267.	1.5	28
216	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. Cancer Treatment Reviews, 2022, 104, 102337.	3.4	6
217	Immune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficacy. Frontiers in Immunology, 2022, 13, 826577.	2.2	3
218	How asymmetric DNA replication achieves symmetrical fidelity. Nature Structural and Molecular Biology, 2021, 28, 1020-1028.	3.6	12
219	A Simple Bypass Assay for DNA Polymerases Shows Hypermutating Variants Associated with Cancer Show Mechanistic Differences In Vitro. SSRN Electronic Journal, 0, , .	0.4	0
220	Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 2653.	1.8	35
221	Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition. Scientific Reports, 2022, 12, 2570.	1.6	5
222	Cadherinâ€'16 inhibits thyroid carcinoma cell proliferation and invasion. Oncology Letters, 2022, 23, 145.	0.8	3
223	Four-Year Disease-Free Remission in a Patient With POLE Mutationâ€"Associated Colorectal Cancer Treated Using Antiâ€"PD-1 Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 218-223.	2.3	4
224	Polymerase Epsilon-Associated Ultramutagenesis in Cancer. Cancers, 2022, 14, 1467.	1.7	9
225	Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group. Frontiers in Oncology, 2022, 12, 805613.	1.3	16
226	A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma. International Journal of Gynecological Pathology, 2022, 41, 541-551.	0.9	10
227	Two-Way Development of the Genetic Model for Endometrial Tumorigenesis in Mice: Current and Future Perspectives. Frontiers in Genetics, 2021, 12, 798628.	1.1	5
228	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discovery, 2022, 12, 1435-1448.	7.7	28
229	Inferring Potential Cancer Driving Synonymous Variants. Genes, 2022, 13, 778.	1.0	1

#	Article	IF	Citations
230	Clinical management of metastatic colorectal cancer in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2022, 72, 372-401.	157.7	167
231	High prevalence of unusual KRAS, NRAS, and BRAF mutations in POLE<scp>â€</scp>hypermutated colorectal cancers. Molecular Oncology, 2022, 16, 3055-3065.	2.1	0
232	Efficient discrimination against RNA-containing primers by human DNA polymerase Îµ. Scientific Reports, 2022, 12, .	1.6	4
233	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. Journal of Clinical Investigation, 2022, 132, .	3.9	9
234	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. Immunotherapy, 0, , .	1.0	3
237	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. Nature Genetics, 2022, 54, 996-1012.	9.4	30
238	Enhanced polymerase activity permits efficient synthesis by cancer-associated DNA polymerase Ïµ variants at low dNTP levels. Nucleic Acids Research, 2022, 50, 8023-8040.	6.5	4
239	POLE/POLD1 mutation and tumor immunotherapy. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	42
240	Colorectal cancer immunotherapy-Recent progress and future directions. Cancer Letters, 2022, 545, 215816.	3.2	32
242	Development of Predictive Biomarkers to Immunotherapy in Head and Neck Cancer. , 2022, , .		0
243	Characterization of hotspot exonuclease domain mutations in the DNA polymerase Ïµ gene in endometrial cancer. Frontiers in Oncology, 0, 12, .	1.3	3
244	CancÃ©rogenÃ¨se et variants faux sens pathogÃ¨nes duÂdomaine exonuclÃ©asique des ADN polymÃ©rases Îµ et Î´. Medecine/Sciences, 2022, 38, 763-765.	0.0	0
246	Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment. Expert Opinion on Therapeutic Targets, 2022, 26, 923-936.	1.5	6
247	NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. Scientific Reports, 2022, 12, .	1.6	2
248	Using canavanine resistance to measure mutation rates in Schizosaccharomyces pombe. PLoS ONE, 2023, 18, e0271016.	1.1	1
249	Oncotherapeutic Strategies in Early Onset Colorectal Cancer. Cancers, 2023, 15, 552.	1.7	4
250	Challenges and exploration for immunotherapies targeting cold colorectal cancer. World Journal of Gastrointestinal Oncology, 0, 15, 55-68.	0.8	3
251	From cue to meaning: The involvement of POLD1 gene in DNA replication, repair and aging. Mechanisms of Ageing and Development, 2023, 211, 111790.	2.2	2

#	Article	IF	Citations
252	POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. International Journal of Molecular Sciences, 2023, 24, 6849.	1.8	4
253	A novel somatic mutation in POLE exonuclease domain associated with ultra-mutational signature and MMR deficiency in endometrial cancer: a case report. Diagnostic Pathology, 2023, 18, .	0.9	1
254	Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer. British Journal of Cancer, 2023, 128, 1582-1591.	2.9	7
255	Characterization of POLE c.1373Aâ€‰>â€‰T p.(Tyr458Phe), causing high cancer risk. Molecular Genetics and Genomics, 0, , .	1.0	0
256	Genotypeâ€“Phenotype Correlations in Autosomal Dominant and Recessive APC Mutation-Negative Colorectal Adenomatous Polyposis. Digestive Diseases and Sciences, 0, , .	1.1	2
257	Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins. American Journal of Surgical Pathology, 2023, 47, 589-598.	2.1	5
258	Case report: POLE (P286R) mutation in a case of recurrent intestinal leakage and its treatment. Frontiers in Oncology, 0, 13, .	1.3	1
259	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12
260	Prospects of POLD1 in Human Cancers: A Review. Cancers, 2023, 15, 1905.	1.7	2
261	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. Pathology Research and Practice, 2023, 247, 154473.	1.0	1
264	RÃ©parations de l'ADN. , 2023, , 101-107.		0
265	The current status and prospect of immunotherapy in colorectal cancer. Clinical and Translational Oncology, 2024, 26, 39-51.	1.2	4
270	Alternative Mechanisms of Mutagenesis at mCpG Sites during Replication and Repair. Molecular Biology, 2023, 57, 584-592.	0.4	0
274	Case Report: Cancer spectrum and genetic characteristics of a de novo germline POLD1 p.L606M variant-induced polyposis syndrome. Frontiers in Oncology, 0, 13, .	1.3	0
288	POLE-Mutant Colon Adenocarcinomaâ€”Case Presentation and Histopathological Evaluation. Journal of Gastrointestinal Cancer, 0, , .	0.6	0